- Policy
- Antidepressant Pristiq’s first generic seeks approval
- by Lee, Tak-Sun Feb 13, 2020 06:27am
- Apparently, generic makers are knocking on the door of depression medication Pristiq ER tablet. This is the first time the original’s saline base-modified drug is applying for an approval. On Feb. 10, Korea’s Ministry of Food and Drug Safety (MFDS) notified the Pristriq’s patent holder Pfizer that a drug with desvenlafaxine, the origi
- Policy
- Optimal substance derived by AI, entering clinical trials
- by Lee, Tak-Sun Feb 12, 2020 06:31am
- New drug candidates using the artificial intelligence (AI) drug development platform entered clinical trials for the first time in Korea. The company plans to develop the material as a new global drug. The Ministry of Food and Drug Safety approved the Phase I trial of PHI-101, a candidate for the treatment of acute myeloid leukemia (AML) f
- Policy
- “Outbreak spreading locally, need to deny Chinese traveler"
- by Lee, Jeong-Hwan Feb 12, 2020 06:31am
- Professor Choi Jae Wook at Korea University Department of Preventive Medicine raised his voice and said, “How could government affirm that the novel coronavirus has not started transmitting throughout Korea? This is the government mocking the people and medical experts. We should not ignore the possibility of the current number of confirmed
- Policy
- Meqsel+Rafinlar combination NSCLC indication reimbursed
- by Kim, Jung-Ju Feb 12, 2020 06:27am
- Korea’s top healthcare reimbursement decision-making body has passed listing of Yooyoung Pharmaceutical’s chronic constipation treatment Rucalo tablet (prucalopride succinate) and expanded reimbursement on Novartis Korea’s Meqsel (trametinib dimethyl sulfoxide) plus Rafinlar (dabrafenib mesylate) combination therapy. The revised List of Re
- Policy
- Strensiq, a rare disease treatment, passed the Committee
- by Lee, Hye-Kyung Feb 11, 2020 06:28am
- Strensiq, a rare disease treatment , passed the Pharmaceutical Benefits Advisory Committee On the 6th, the HIRA (Director Seung-taek Kim) revealed the results of the review by the Pharmaceutical Benefits Advisory Committee on the adequacy of the medical benefits of the drug application. Only one drug has been evaluated for adequacy of r
- Policy
- Phase 3 trial for Korea-made DPP-4 + SGLT-2 approved
- by Lee, Tak-Sun Feb 10, 2020 06:31am
- Apparently, Phase III clinical protocols of two new Korea-made anti-diabetic treatments based on DPP-4 inhibitor, Suganon (evoglitin by Dong-A ST) and Zemiglo (gemigliptin by LG Chem), have been approved to test their combination efficacy with SGLT-2 inhibitor drug. Among nine new dipeptidyl peptidase 4 (DPP-4) inhibitor drugs competing
- Policy
- HIRA to tighten personal data protection for committees
- by Lee, Hye-Kyung Feb 10, 2020 06:30am
- Drug reimbursement feasibility deliberating Health Insurance Review and Assessment Service (HIRA) plans to tighten operational regulation for its associated committees. The revised regulation would minimize collection of committee member’s private information and generally strengthen protection of personal information. HIRA’s Benefit L
- Policy
- Rucalo newly listed, Meqsel+Rafinlar expands reimbursement
- by Kim, Jung-Ju Feb 10, 2020 06:30am
- Healthcare reimbursement would be granted on Yooyoung Pharmaceutical’s chronic constipation treatment Rocalo tablet (prucalopride succinate) soon at a price of 100 won a unit. Used to treat BRAF V600E mutation-confirmed metastatic melanoma, Novartis Korea’s Meqsel (trametinib dimethyl sulfoxide) plus Rafinlar (dabrafenib mesylate) combin
- Policy
- NIH, urgently promotes 2019n-CoV vaccine research
- by Kim, Jung-Ju Feb 7, 2020 06:32am
- Health authorities urgently push forward research to develop 2019n-CoV treatments and vaccines. After the MERS outbreak, it will strengthen its research capabilities and begin research on viral pathogenicity within this month. The National Institutes of Health (Director Hyun-Young Park), in the Centers for Disease Control and Prevention
- Policy
- Feb shortage prevention drug list: 641 items with Vivaquine
- by Lee, Hye-Kyung Feb 7, 2020 06:32am
- Myung In Pharmaceutical’s Vivaquine tablet (primaquine phosphate) has been designated as a shortage prevention drug as compensation for high production cost. The maximum price is set at 309 won. Health Insurance Review and Assessment Service (HIRA) recently disclosed new list of shortage prevention drug as of February 2020. ‘Shorta
